Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2024

  1. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

  2. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology, Vol. 228

  3. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

2023

  1. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

  2. Location, morphology and invasiveness of lateral spreading tumors in the colorectum differ between two large cohorts from an eastern and western country

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 6, pp. 440-449

  3. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

    Liver International, Vol. 42, Núm. 8, pp. 1891-1901

2021

  1. Compound endoscopic morphological features for identifying non-pedunculated lesions ≥20 mm with intramucosal neoplasia

    Cancers, Vol. 13, Núm. 21

  2. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics

    Aging, Vol. 13, Núm. 19, pp. 23416-23434

2019

  1. Accuracy of the Narrow-Band Imaging International Colorectal Endoscopic Classification System in Identification of Deep Invasion in Colorectal Polyps

    Gastroenterology, Vol. 156, Núm. 1, pp. 75-87

  2. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

    Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672

2017

  1. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection

    International Journal of Clinical Practice, Vol. 71, Núm. 9